John Copertino

Home John Copertino

14

Oct2023

Inactivating TSC1 and TSC2 alterations, co-mutations, and genomic instability in advanced cancers: Analysis of a real-world (RW) patient population using the Foundation Medicine genomic database

0  
Inactivating TSC1 and TSC2 alterations, co-mutations, and genomic instability in advanced cancers: Analysis of a real-world (RW) patient population using the Foundation Medicine genomic database
October 14, 2023John Copertino

13

Oct2023

Phase 2, Multicenter Open-label Basket Trial of nab-Sirolimus for Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 (PRECISION 1)

0  
Phase 2, Multicenter Open-label Basket Trial of nab-Sirolimus for Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 (PRECISION 1)
October 13, 2023John Copertino

13

Oct2023

Real-world (RW) characterization and frequency of TSC1 and/or TSC2 alterations collected from tumor tissue and liquid biopsies from the Tempus genomic database in patients with advanced cancer

0  
Real-world (RW) characterization and frequency of TSC1 and/or TSC2 alterations collected from tumor tissue and liquid biopsies from the Tempus genomic database in patients with advanced cancer
October 13, 2023John Copertino

02

Jun2023

Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes (PRECISION 1)

0  
Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes (PRECISION 1)
June 2, 2023John Copertino

26

Mar2023

Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I)

0  
March 26, 2023John Copertino

26

Mar2023

Response to Treatment With nab-Sirolimus Among Patients With Primary Uterine PEComa: A Subanalysis From AMPECT

0  
March 26, 2023John Copertino

16

Jan2023

Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I)

0  
January 16, 2023John Copertino

18

May2022

Aadi Bioscience to Present at the H.C. Wainwright Global Investment Conference

0  
LOS ANGELES, May 18, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (Nasdaq: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that Founder, Chief Executive Officer and President, Neil Desai, Ph.D., and senior members of Aadi’s executive team will participate virtually ... Read More
May 18, 2022John Copertino

12

May2022

UPDATE — Aadi Bioscience Reports First Quarter 2022 Financial Results and Provides a Corporate Update

0  
FYARRO net product sales of $2.3 million in partial first quarter Dosing of patients initiated in PRECISION 1, a Phase 2 tumor-agnostic registration-directed trial evaluating nab-sirolimus in TSC1 or TSC2 altered solid tumors Conference call to be held today at 8:30 am EDT LOS ANGELES, May 12, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical ... Read More
May 12, 2022John Copertino

09

May2022

Aadi Bioscience Announces Collaborations with Next Generation Sequencing Leaders

0  
Company enters into collaborations with leading next generation sequencing (NGS) companies to facilitate trial enrollment for PRECISION 1, the Company’s Phase 2 registrational trial Collaborations will expedite identification of advanced cancer patients with Tuberous Sclerosis Complex 1 and 2 (“TSC1” and “TSC2”) inactivating alterations, a population with a projected US incidence ... Read More
May 9, 2022John Copertino